Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cerecor Inc. stock logo
CERC
Cerecor
$14.41
-9.5%		$2.60
$1.98
▼
$4.50
$1.38B1.441.27 million shs1.58 million shs
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
$4.13
-3.5%		$7.91
$4.03
▼
$18.11
$80.01M2.63864,671 shs983,757 shs
Harrow, Inc. stock logo
HROW
Harrow
$28.15
-0.3%		$34.20
$26.96
▼
$54.85
$1.06B0.19607,209 shs440,123 shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.41
$1.79
$1.17
▼
$3.90
$69.40M0.61252,120 shs30,489 shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cerecor Inc. stock logo
CERC
Cerecor
0.00%0.00%0.00%0.00%-17.33%
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-3.50%-4.62%-47.59%-54.96%-76.72%
Harrow, Inc. stock logo
HROW
Harrow
-0.32%-2.09%-18.29%-26.79%-27.62%
MediciNova, Inc. stock logo
MNOV
MediciNova
0.00%-2.76%-51.38%+6.82%+15.57%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cerecor Inc. stock logo
CERC
Cerecor
$14.41
-9.5%		$2.60
$1.98
▼
$4.50
$1.38B1.441.27 million shs1.58 million shs
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
$4.13
-3.5%		$7.91
$4.03
▼
$18.11
$80.01M2.63864,671 shs983,757 shs
Harrow, Inc. stock logo
HROW
Harrow
$28.15
-0.3%		$34.20
$26.96
▼
$54.85
$1.06B0.19607,209 shs440,123 shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.41
$1.79
$1.17
▼
$3.90
$69.40M0.61252,120 shs30,489 shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cerecor Inc. stock logo
CERC
Cerecor
0.00%0.00%0.00%0.00%-17.33%
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-3.50%-4.62%-47.59%-54.96%-76.72%
Harrow, Inc. stock logo
HROW
Harrow
-0.32%-2.09%-18.29%-26.79%-27.62%
MediciNova, Inc. stock logo
MNOV
MediciNova
0.00%-2.76%-51.38%+6.82%+15.57%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cerecor Inc. stock logo
CERC
Cerecor
0.00
N/AN/AN/A
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
2.75
Moderate Buy$39.57858.15% Upside
Harrow, Inc. stock logo
HROW
Harrow
2.60
Moderate Buy$66.17135.05% Upside
MediciNova, Inc. stock logo
MNOV
MediciNova
2.71
Moderate Buy$7.75449.65% Upside

Current Analyst Ratings Breakdown

Latest MNOV, CRBP, CERC, and HROW Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/16/2026
Harrow, Inc. stock logo
HROW
Harrow
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
10/15/2026
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/7/2026
Harrow, Inc. stock logo
HROW
Harrow
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$63.00
9/29/2026
MediciNova, Inc. stock logo
MNOV
MediciNova
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
9/17/2026
MediciNova, Inc. stock logo
MNOV
MediciNova
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$6.00
9/17/2026
MediciNova, Inc. stock logo
MNOV
MediciNova
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$6.00
9/14/2026
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$35.00
9/9/2026
Harrow, Inc. stock logo
HROW
Harrow
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOutperform$45.00
9/9/2026
Harrow, Inc. stock logo
HROW
Harrow
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong Sell ➝ Hold
9/9/2026
Harrow, Inc. stock logo
HROW
Harrow
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOutperform$45.00
9/2/2026
MediciNova, Inc. stock logo
MNOV
MediciNova
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 10/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cerecor Inc. stock logo
CERC
Cerecor
$6.70M206.49N/AN/A$0.22 per share65.50
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/AN/AN/AN/A$8.40 per shareN/A
Harrow, Inc. stock logo
HROW
Harrow
$272.30M3.88$0.86 per share32.67$1.41 per share19.96
MediciNova, Inc. stock logo
MNOV
MediciNova
$410K169.27N/AN/A$0.85 per share1.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cerecor Inc. stock logo
CERC
Cerecor
-$63.50M-$0.57N/AN/AN/A-1,194.82%-261.82%-133.96%N/A
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-$78.54M-$6.19N/AN/AN/AN/A-87.05%-74.22%11/11/2026 (Estimated)
Harrow, Inc. stock logo
HROW
Harrow
-$5.14M-$1.00N/A12.91N/A-13.51%-38.00%-3.37%11/9/2026 (Estimated)
MediciNova, Inc. stock logo
MNOV
MediciNova
-$12M-$0.21N/AN/AN/A-1,168.70%-26.51%-24.39%11/12/2026 (Estimated)

Latest MNOV, CRBP, CERC, and HROW Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
MediciNova, Inc. stock logo
MNOV
MediciNova
-$0.06N/AN/AN/A$0.05 millionN/A
11/11/2026Q3 2026
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-$1.2141N/AN/AN/A$2.00 millionN/A
11/9/2026Q3 2026
Harrow, Inc. stock logo
HROW
Harrow
$0.17N/AN/AN/A$98.47 millionN/A
8/13/2026Q2 2026
MediciNova, Inc. stock logo
MNOV
MediciNova
-$0.0633-$0.05+$0.0133-$0.05$0.08 million$0.46 million
8/10/2026Q2 2026
Harrow, Inc. stock logo
HROW
Harrow
-$0.1788-$0.46-$0.2813-$0.46$70.35 million$70.66 million
8/6/2026Q2 2026
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-$1.26-$1.81-$0.55-$1.81N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cerecor Inc. stock logo
CERC
Cerecor
N/AN/AN/AN/AN/A
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/AN/AN/AN/AN/A
Harrow, Inc. stock logo
HROW
Harrow
N/AN/AN/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cerecor Inc. stock logo
CERC
Cerecor
0.79
2.19
2.18
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/A
5.71
5.71
Harrow, Inc. stock logo
HROW
Harrow
19.70
2.24
2.08
MediciNova, Inc. stock logo
MNOV
MediciNova
N/A
8.75
8.75

Institutional Ownership

CompanyInstitutional Ownership
Cerecor Inc. stock logo
CERC
Cerecor
62.84%
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
64.64%
Harrow, Inc. stock logo
HROW
Harrow
72.76%
MediciNova, Inc. stock logo
MNOV
MediciNova
9.90%

Insider Ownership

CompanyInsider Ownership
Cerecor Inc. stock logo
CERC
Cerecor
45.70%
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
3.50%
Harrow, Inc. stock logo
HROW
Harrow
12.80%
MediciNova, Inc. stock logo
MNOV
MediciNova
14.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cerecor Inc. stock logo
CERC
Cerecor
3196.01 millionN/ANot Optionable
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
3618.67 million18.02 millionOptionable
Harrow, Inc. stock logo
HROW
Harrow
37337.49 million32.69 millionOptionable
MediciNova, Inc. stock logo
MNOV
MediciNova
649.22 million42.33 millionOptionable

Recent News About These Companies

MediciNova reports mixed trial data as analysts rate MediciNova stock
October 14, 2026  |  ad-hoc-news.deA
Phibro Animal Health (NASDAQ:PAHC) and MediciNova (NASDAQ:MNOV) Head to Head Survey
October 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31109475
MediciNova, Inc. (NASDAQ:MNOV) Receives Consensus Rating of "Moderate Buy" from Analysts
October 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-medicinova-inc-nasdaq-mnov-receives-consensus-rating-of-moderate-buy-from-analysts-2026-10-09/
MediciNova (NASDAQ:MNOV) Stock Price Breaks Above Two Hundred Day Moving Average - Here's Why
October 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-medicinova-nasdaq-mnov-stock-price-breaks-above-two-hundred-day-moving-average-heres-why-2026-10-07/
MediciNova to Participate in the Maxim Growth Summit
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375268/7767/en/medicinova-to-participate-in-the-maxim-growth-summit.html
MediciNova stock gained 9.20 percent after mixed Phase 2 data
October 6, 2026  |  ad-hoc-news.deA
MediciNova (NASDAQ:MNOV) Major Shareholder Sells $1,728,000.00 in Stock
September 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-medicinova-nasdaq-mnov-major-shareholder-sells-172800000-in-stock-2026-09-29/
H.C. Wainwright Reiterates Buy Rating on MediciNova (MNOV)
September 29, 2026  |  streetinsider.comhttps://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+MediciNova+%28MNOV%29/27117068.html
MediciNova stock tumbles on mixed Phase 2 NAFLD trial data
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/medicinova-stock-tumbles-mixed-phase-132051602.html
MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/medicinova-shares-fall-phase-2-135826324.html
Stock Traders Buy Large Volume of Put Options on MediciNova (NASDAQ:MNOV)
September 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-stock-traders-buy-large-volume-of-put-options-on-medicinova-nasdaq-mnov-2026-09-28/
MediciNova Reports Phase 2 MN-001 Data In T2DM-Associated NAFLD; Stock Plunges In Premarket
September 28, 2026  |  rttnews.comhttps://www.rttnews.com/3694277/medicinova-reports-phase-2-mn-001-data-in-t2dm-associated-nafld-stock-plunges-in-premarket.aspx
MediciNova reports Phase 2 MN-001 trial data
September 28, 2026  |  grafa.comG
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
September 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/28/3369686/7767/en/medicinova-announces-topline-results-from-mn-001-natg-202-clinical-trial-of-mn-001-tipelukast.html
MNOV Stock In Focus As COMBAT-ALS Completes Double-Blind Phase; Results Due By Year-End
September 24, 2026  |  rttnews.comhttps://www.rttnews.com/3693723/mnov-stock-in-focus-as-combat-als-completes-double-blind-phase-results-due-by-year-end.aspx
MediciNova Announces Last Patient, Last Visit in Double-Blind Portion of COMBAT-ALS Phase 2b/3 Trial of MN-166 for ALS
September 24, 2026  |  quiverquant.comQ
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
September 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/24/3368112/7767/en/medicinova-announces-completion-of-last-patient-last-visit-in-the-double-blind-portion-of-the-phase-2b-3-combat-als-trial-of-mn-166-ibudilast.html
Roth Capital initiates coverage of MediciNova with buy rating
September 17, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/roth-capital-initiates-coverage-of-medicinova-with-buy-rating/ar-AA2csJUh
Can MediciNova's Upcoming MN-166 And MN-001 Readouts Change The Investment Narrative?
September 16, 2026  |  rttnews.comhttps://www.rttnews.com/3691446/can-medicinova-s-upcoming-mn-166-and-mn-001-readouts-change-the-investment-narrative.aspx
MediciNova to Participate in Two Investor Conferences in September
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357430/7767/en/medicinova-to-participate-in-two-investor-conferences-in-september.html
MediciNova stock gains as price moves above 200-day line
September 5, 2026  |  ad-hoc-news.deA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cerecor stock logo

Cerecor NASDAQ:CERC

Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Corbus Pharmaceuticals stock logo

Corbus Pharmaceuticals NASDAQ:CRBP

$4.13 -0.15 (-3.50%)
Closing price 10/22/2026 04:00 PM Eastern
Extended Trading
$4.07 -0.06 (-1.57%)
As of 08:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Harrow stock logo

Harrow NASDAQ:HROW

$28.15 -0.09 (-0.32%)
Closing price 10/22/2026 04:00 PM Eastern
Extended Trading
$28.18 +0.03 (+0.12%)
As of 08:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

MediciNova stock logo

MediciNova NASDAQ:MNOV

$1.41 0.00 (0.00%)
Closing price 10/22/2026 04:00 PM Eastern
Extended Trading
$1.41 0.00 (0.00%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas